J O C Motta1, R N R Sampaio. 1. Hospital Universitário de Brasília, Brasilia-DF, Brazil. jorgeth@brturbo.com.br
Abstract
BACKGROUND: Cutaneous leishmaniasis is an infectious re-emerging disease that has increased in incidence worldwide. Antimony, a highly toxic drug, remains the first choice therapy to treat it. Liposomal amphotericin B is active against Leishmania and is less toxic than antimony. OBJECTIVE: To compare low-dose liposomal amphotericin B with N-methyl glucamine for the treatment of American cutaneous leishmaniasis. PATIENTS/ METHODS: In a controlled open-label trial 35 patients with a localized form of American cutaneous leishmaniasis were included. They were allocated to a first group treated with 1.5 mg/kg/day of liposomal amphotericin B for 5 days, or to a second one treated with 20 mgSbV/kg/day of N-methyl glucamine for 20 days. RESULTS: In the first group, 50% and 81% of patients experienced a clinical cure and clinical improvement respectively. There was a 100% clinical cure in the second group. CONCLUSION: Liposomal amphotericin B seems to be promising and safe for the treatment of American cutaneous leishmaniasis.
BACKGROUND:Cutaneous leishmaniasis is an infectious re-emerging disease that has increased in incidence worldwide. Antimony, a highly toxic drug, remains the first choice therapy to treat it. Liposomal amphotericin B is active against Leishmania and is less toxic than antimony. OBJECTIVE: To compare low-dose liposomal amphotericin B with N-methyl glucamine for the treatment of American cutaneous leishmaniasis. PATIENTS/ METHODS: In a controlled open-label trial 35 patients with a localized form of American cutaneous leishmaniasis were included. They were allocated to a first group treated with 1.5 mg/kg/day of liposomal amphotericin B for 5 days, or to a second one treated with 20 mgSbV/kg/day of N-methyl glucamine for 20 days. RESULTS: In the first group, 50% and 81% of patients experienced a clinical cure and clinical improvement respectively. There was a 100% clinical cure in the second group. CONCLUSION: Liposomal amphotericin B seems to be promising and safe for the treatment of American cutaneous leishmaniasis.
Authors: Camila F Amorim; Luiza Galina; Natália B Carvalho; Nathalia D M Sperotto; Kenia Pissinate; Pablo Machado; Maria M Campos; Luiz A Basso; Valnês S Rodrigues-Junior; Edgar M Carvalho; Diógenes Santiago Santos Journal: PLoS One Date: 2017-12-27 Impact factor: 3.240
Authors: Ludovic Reveiz; Ana Nilce Silveira Maia-Elkhoury; Rubén Santiago Nicholls; Gustavo Adolfo Sierra Romero; Zaida E Yadon Journal: PLoS One Date: 2013-04-29 Impact factor: 3.240